Alain Corbani, head of mining at Montbleu Finance and manager of the Global Gold and Precious Fund, sees the gold price reaching US$5,000 per ounce in the near term.
He sees real interest rates and the US dollar as the key factors to watch, but noted that other elements are also adding tailwinds.
Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.
The growing prevalence of chronic diseases like cancer and diabetes is driving increasing innovation in medical device technology. In 2024 alone, 30 new devices were approved by the US Food and Drug Administration (FDA).
Wearable medical devices and the use of artificial intelligence in medical technology are two key trends in this sector.
Investors who want exposure to this wave of growth may want to consider NASDAQ small-cap medical device stocks. Below is a list of the top NASDAQ medical device companies based on year-on-year gains.
All data was compiled on December 31, 2025, using TradingView’s stock screener, and the medical device makers listed below had market caps between US$50 million and US$500 million at that time.
Year-on-year gain: 50.86 percent
Market cap: US$173.24 million
Share price: US$3.50
MDxHealth is a commercial-stage precision diagnostics company specializing in molecular tests for urologic cancers, particularly prostate cancer, using genomic, epigenetic and exosomal technologies. Its US headquarters and operations are located in Irvine, California.
The company offers non-invasive and tissue-based diagnostic assays that run on standard PCR platforms.
In September, MDxHealth acquired Exosome Diagnostics from Bio-Techne (NASDAQ:TECH) for US$15 million, adding the ExoDx Prostate urine test to its portfolio. The deal also includes a CLIA-certified clinical laboratory and related assets. The deal is expected to generate over US$20 million in revenue in 2026.
Year-on-year gain: 50.13 percent
Market cap: US$269.6 million
Share price: US$5.82
KORU Medical Systems develops and manufactures medical devices and supplies in the US and internationally, with a focus on mechanical infusion products. Its Freedom Syringe Infusion System first received FDA clearance in 1994.
Based on this system, its primary products include the Freedom60 and FreedomEdge syringe infusion systems, Precision Flow Rate Tubing and High-Flo Subcutaneous Safety Needle Sets.
KORU Medical Systems submitted a 510(k) premarket notification to the FDA on December 30, 2025, seeking clearance for its FreedomEdge system to deliver Phesgo — a HER2+ breast cancer targeted biologic — subcutaneously, targeting infusion centers to cut chair time and boost efficiency.
The company stated this is part of its strategy to expand the indications of FreedomEdge to the wider oncology infusion center market.
Year-on-year gain: 1.71 percent
Market cap: US$86.81 million
Share price: US$1.19
Vivani Medical is a clinical-stage biopharmaceutical company developing miniature, long-term subdermal drug implants using its proprietary NanoPortal technology to treat chronic conditions like obesity and type 2 diabetes.
Headquartered in Alameda, California, Vivani focuses on GLP-1 implants that provide steady drug release over six months to improve adherence and tolerability compared to daily pills or weekly injections.
In August, Vivani Medical reported positive Phase 1 results from its LIBERATE-1 trial of the NPM-115 exenatide implant, confirming safety and steady drug release for obesity treatment without major side effects.
The company plans to rapidly advance its NPM-139 semaglutide implant after it achieved preclinical results of sustained 20 percent weight loss. It is planning a Phase 1 clinical study in the first half of 2026.
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
2025 marked a turning point for investment in the cannabis sector, shifting the focus toward operational resilience and consolidation after a sluggish 2024.
Key market drivers included an upswing in merger and acquisition (M&A) activity as stronger multi-state operators (MSOs) acquired distressed assets, alongside pivotal regulatory developments.
The central theme for the year was the expected US federal shift to Schedule III, a policy rollercoaster that culminated in an executive order to expedite rescheduling, focusing investor flows into scaled, cashflow-positive MSOs.
Internationally, incremental legalization in Europe, particularly the momentum in Germany, broadened the global footprint and provided new export channels for North American producers.
Within market trends, profitability pivoted away from bulk flower to high-margin consumables, with infused pre-rolls and edibles driving category growth and supporting a rerating of resilient operators.
After 2024’s punishing drawdowns, cannabis navigated a high-stakes policy rollercoaster in 2025.
The sector bottomed in Q1 as anticipated US Drug Enforcement Administration (DEA) rescheduling hearings were delayed, but ignited in late Q3 and Q4 as the narrative shifted toward a decisive executive-led reclassification.
This momentum culminated in US President Donald Trump’s December 18 executive order, which expedites rescheduling and CBD access. It triggered a parabolic surge followed by a violent ‘sell the news’ correction.
“Cannabis is not just a volatile sector or industry. It is the most volatile place,” said Dan Ahrens, managing director and portfolio manager of the AdvisorShares Pure US Cannabis ETF (ARCA:MSOS). “It just proves the point, once again, that we really, really need this federal reform to be officially completed.”
Indeed, 2025 brought plenty of ups and downs. The year opened with Schedule III buzz, which came after prior Department of Health and Human Services recommendations and initial DEA scheduling proposals from late 2024; however, proceedings ground to a halt after the DEA postponed a key January hearing by over 180 days due to administrative turnover, bias claims and leadership gaps post-election. These disruptiosn kept Section 280E tax penalties in place and banking access frozen, keeping margins for MSOs compressed.
Meanwhile, House spending bills included language prohibiting the Department of Justice (DoJ) from spending any funds on rescheduling efforts, while Senate Farm Bill revisions redefined hemp to exclude intoxicating derivatives like delta-8 THC, capping them at trace levels and effectively imposing a nationwide hemp ban on high-potency alternatives.
The MSOS ETF’s portfolio construction exemplified the broader trend of investor flows concentrating into scaled, cash-flow-positive MSOs amid reform volatility. The fund’s top three holdings — Curaleaf Holdings (CSE:CURA,OTCQX:CURLF), Trulieve Cannabis (CSE:TRUL,OTCQX:TCNNF) and Green Thumb Industries (CSE:GTII,OTCQX:GTBIF) — accounted for over 68 percent of its total holdings as of December 31, underscoring confidence in these operators as resilient proxies for US cannabis maturation while smaller single-state players face dilution.
MSOS managers reinforced the shift in the year’s third quarter by trimming three underperformers from the ETF: 4Front Ventures (CSE:FFNT), Lowell Farms (CSE:LOWL) and Gold Flora.
Despite stalls in momentum, Trump kept hope alive in the cannabis sector throughout the year.
In September, he called cannabis reform an “80-20 issue” with broad public backing, and posted a Truth Social video promoting CBD for seniors and suggesting Medicaid coverage.
Those moves, alongside Representative Greg Steube’s (R-FL) Marijuana 1-to-3 Act, aimed at legislatively shifting cannabis to Schedule III, drove a surge in Q3 without any underlying procedural progress.
As mentioned, the December 18 executive order injected fresh life into the sector, directing the DoJ and DEA to expedite cannabis rescheduling to Schedule III, while launching a CMS Innovation Center pilot for federal health programs to cover hemp-derived CBD as early as April 2026, with up to US$500 annual reimbursement for eligible patients.
CMS Administrator Mehmet Oz previously endorsed Medicare reimbursement for CBD therapies during his confirmation hearings, framing them as “low-risk, high-impact” options for age-related ailments.
2025 brought incremental legalization or medical frameworks in multiple jurisdictions, including Czechia, Malta, Poland, Switzerland and Luxembourg, broadening the investable global footprint.
This continental momentum has directly boosted North American producers through export ramps and licensing deals, with Canadian licensed producers capturing 43 percent of Germany’s Q2 imports alone.
The country’s CanG framework and adult‑use reform, which came into effect in April 2024, have made it Europe’s most important legal market, with 2025 medical sales expected to see explosive year-on-year growth.
In 2025, cannabis companies pivoted toward operational resilience and product innovation amid persistent commoditization pressures. After 2024’s wholesale flower price declines, down roughly 32 percent since 2021 by some estimates, stronger MSOs like Tilray Brands (TSX:TLRY,NASDAQ:TLRY) are demonstrating pricing power through branded products and category expansion into edibles, vapes and infused pre-rolls.
Deal flow rebounded from 2024’s US$1.17 billion trough, with US transactions reaching US$2.1 billion.
Against that backdrop, cash-rich MSOs pursued distressed roll-ups in oversupplied states like California and New York, with Vireo Growth’s (CSE:VREO,OTCQX:VREOF) acquisitions in Minnesota and New York exemplifying the trend, achieving critical mass with premium valuations amid hemp restrictions.
Private equity and creative deal structures dominated in the cannabis market, preparing operators for federal reform, while consolidating fragmented retail.
2025 marked a transformative year for cannabis, with regulatory breakthroughs and market maturation set against the backdrop of volatility. Trump’s execuctive order has brought new life into the sector in the US with the promise of not only banking and tax relief, but also bipartisan momentum for normalization; however, investors remain cautious.
“Everybody is waiting for it to be real and for it to be completed. Because even though we think the executive order was huge … nothing’s complete yet. Nothing’s official yet,” explained Ahrens.
Looking to 2026, he emphasized that the path forward for cannabis isn’t a straight line, but rather a series of volatile ‘waves’ tied to incremental regulatory milestones. Ahrens anticipates that while the finalization of Schedule III should trigger an initial move, it is merely the first domino; subsequent upside depends on the DoJ providing clear guidance for state-legal adult-use programs and the eventual passage of banking reform.
While he does foresee cannabis stocks uplisting to major exchanges, and Big Pharma companies beginning to make acquisitions in the space, Ahrens remains cautious about timing, noting that even with a signed order, large institutional banks will likely keep the ‘blockade’ in place until the legal ink is truly dry.
Ultimately, while 2025’s executive action has established a concrete foundation for federal reform in the US, the cannabis sector remains poised in a state of high-stakes volatility, with its full maturation dependent on official completion of milestones in 2026 and beyond.
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
(TheNewswire)
Crown Porphyry-Stockwork Drill Targets Confirmed
Vancouver, British Columbia, January 7th, 2026 TheNewswire Prismo Metals Inc. (‘Prismo’ or the ‘Company’) (CSE: PRIZ,OTC:PMOMF) (OTCQB: PMOMF) is pleased to announce it has received final assay results for samples taken at the Silver King Project from the Crown porphyry target area located on the east side of the property (Fig. 1).
Click Image To View Full Size
Figure 1. Map showing the location of the Crown porphyry and stockwork and Black Diamond replacement exploration targets at the Silver King project. Claim boundaries are shown in yellow.
Overlimit silver assays have been received for the samples taken in late 2025, showing high grade silver mineralization associated with quartz-sulfide veins hosted by the Crown porphyry (Fig 2, Table 1). These assays provide evidence for a high-priority drill target, especially when taken in conjunction with the high gold assays reported previously for the stockwork intrusion (see the News Release of Dec. 3, 2025).
‘Prismo optioned Silver King with existing drill targets around the historically significant high-grade silver mine. Based on the geology and its location in a well mineralized region, we believed that additional mineralization was also likely present. Our work in the second half of 2025 indicates that we were correct, and we now have exceptional drill targets at the Crown porphyry and adjacent Black Diamond replacement areas,’ stated Craig Gibson, Chief Exploration Officer of the Company. He added, ‘With the high-grade gold assays reported in December and the copper assays at the Black Diamond replacement, we now have a very significant precious-metal and copper target at Silver King similar to other areas in this well mineralized district that includes the Magma mine and the Resolution copper deposit.’
‘These additional assay results along with the IP survey information continue to enhance and support our exploration thesis of the Silver King mine and surrounding areas,’ stated Gordon Aldcorn. ‘This modern-day review has yielded additional drill targets and prospective structures to our program in this already very strategically located project.’
Table 1. Assay results for selected samples from the Crown porphyry stockwork
|
Sample |
Location |
Easting |
Northing |
Width m |
Au g/t |
Ag g/t |
Cu % |
Pb % |
Zn % |
|
544559 |
Crown porphyry |
492681 |
3687905 |
0.5 m |
0.02 |
18.91 |
0.02 |
0.07 |
0.04 |
|
544561 |
Crown porphyry |
492673 |
3687904 |
2 m |
0.02 |
177 |
0.07 |
0.37 |
0.02 |
|
544563 |
Crown porphyry |
492613 |
3687848 |
0.5m |
0.03 |
176 |
– |
0.09 |
0.01 |
|
544591* |
Crown porphyry |
492799 |
3687851 |
1.0 |
5.19 |
46.44 |
0.05 |
0.21 |
0.06 |
|
544592* |
Crown porphyry |
492793 |
3687823 |
1.0 |
4.06 |
13.97 |
0.02 |
0.10 |
0.07 |
*Assays previously released in News Release of December 3, 2025.
Click Image To View Full Size
Figure 2. Precious metal and copper assays from the Crown porphyry
and the Black Diamond replacement body at the Silver King Project.
IP Survey
The Company also completed a pole-dipole IP survey over a part of the Silver King project in December 2025. This survey was designed to provide some additional 3-dimensional data for areas identified during the initial gradient array survey (see News Release dated December 3, 2025). This new survey confirmed the presence of important chargeability and resistivity anomalies at the Silver King project. The Silver King silver mine appears to be associated with a large low resistivity anomaly located on the contact of the Silver King diorite porphyry (Fig 3). There is also low resistivity anomalies associated with the Crown porphyry and near the replacement mineralization at Black Diamond (Fig 3). The highest chargeability anomalies appear to be associated with the altered country rocks along intrusive contacts, but a chargeability high is also associated with the Crown porphyry stockwork intrusion. The anomaly associated with the Crown porphyry is particularly interesting and can be traced from shallow levels to about 300 meters in depth.
Click Image To View Full Size
Figure 3. IP resistivity map at a depth of 75 meters, overlain on geology and showing the Silver King glory hole (black line), Black Diamond replacement body in red, and the Crown porphyry-stockwork in magenta.
Click Image To View Full Size
Figure 4. IP chargeability at a depth of 75 meters, overlain on geology and showing the Silver King glory hole (black line), Black Diamond replacement body in red, and the Crown porphyry-stockwork in magenta.
Drilling Update
Alain Lambert, CEO of Prismo commented: ‘The results announced today confirm the vast exploration potential at Silver King. While we look forward to drilling these new targets in the future, our plans remain unchanged. Our immediate priority is to undertake our fully funded drill program, as previously announced. This drill campaign will primarily focus on the historic Silver King mine site and will be about 2,000 meters. The objective is to test the upper half of the steeply dipping pipelike Silver King mineralized body as well as potential mineralization adjacent to the dense stockwork that was the focus of historic mining.’
Mr. Lambert added: ‘We are pleased with the steady progress on the permitting front. The collaboration of Forest Service officials demonstrates a clear commitment to supporting mining activities in Arizona.’
Prismo recently announced that the Forest Service, the federal surface land management entity for Silver King, had determined that the Company’s proposed drill plan meets the regulatory requirements for processing, and that such plan is complete, as described in the regulations at 36 CFR 228.4(c).
The Forest Service is currently proceeding with the environmental analysis pursuant to 36 CFR 228(a)(5) in conformity with the National Environmental Policy Act (NEPA). This analysis is proceeding as a Categorical Exclusion, the lowest level of environment reviews applicable to projects that are not expected to have a significant effect on the environment, such as Silver King.
QA/QC
Samples were analyzed by SGS, an internationally recognized analytical lab, with preparation at the Tempe, Arizona facility and analyses at the Burnaby laboratory. Prismo inserts controls samples consisting of a standard pulps and a coarse blanks in the sample stream, and the lab also inserts control samples.
Qualified Person
Dr. Craig Gibson, PhD., CPG., a Qualified Person as defined by NI-43-01 regulations and Chief Exploration Officer and a director of the Company, has reviewed and approved the technical disclosures in this news release.
About Prismo Metals Inc.
Prismo (CSE: PRIZ,OTC:PMOMF) is a mining exploration company focused on advancing its Silver King, Ripsey and Hot Breccia projects in Arizona and its Palos Verdes silver project in Mexico.
Please follow @PrismoMetals on Twitter, Facebook, LinkedIn, Instagram, and YouTube
Prismo Metals Inc.
1100 – 1111 Melville St., Vancouver, British Columbia V6E 3V6 Phone: (416) 361-0737
Contact:
Alain Lambert, Chief Executive Officer alain.lambert@prismometals.com
Gordon Aldcorn, President gordon.aldcorn@prismometals.com
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Information
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as ‘intends’ or ‘anticipates’, or variations of such words and phrases or statements that certain actions, events or results ‘may’, ‘could’, ‘should’, ‘would’ or ‘occur’. This information and these statements, referred to herein as ‘forward-looking statements’, are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management’s expectations and intentions with respect to, among other things: the timing, costs and results of drilling at Silver King; and the intended use of any proceeds raised under recent financings.
These forward-looking statements involve numerous risks and uncertainties, and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: the potential inability of the Company to utilize the anticipated proceeds of the Private Placement as anticipated; and those risks set out in the Company’s public disclosure record on SEDAR+ (www.sedarplus.com) under the Company’s issuer profile.
In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, that the Company will use the proceeds of the Second Tranche as currently anticipated and on the timeline currently expected.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward- looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward- looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
Copyright (c) 2026 TheNewswire – All rights reserved.
News Provided by TheNewsWire via QuoteMedia
(TheNewswire)
Anchors to:
3.50 m@ 1.40 g/t Au and 2.30% Zn (162.50 m to 166.00 m)
including:
0.70 m @ 5.97 g/t Au,18.4 g/t Ag and 10.8% Zn.
4.50 m@ 2.00 g/t Au, 5.75 g/t Ag and 1.22% Zn(188.00 m to 192.50 m),
including:
0.50 m @ 3.30 g/t Au,17.8 g/t Ag and 6.84% Zn (188.00 m to 188.50 m),
2.40 m @ 3.00 g/t Au and 0.78% Zn (190.10 m to 192.50 m), and
0.55 m @ 12.15 g/t Au, 16.1 g/t Ag and 2.66% Zn (191.10 m to 192.50 m).
Drill hole LBX25-096
3.85 m @ 1.92 g/t Au and 0.13% Zn (38.70 m to 42.55 m),
including:
0.60 m @ 2.78 g/t Au, 6.30 g/t Ag and 0.62% Zn (40.60 m to 41.20 m), and
55 m @ 9.59 g/t Au, 5.50 g/t Ag and 0.11% Zn (42.00 m to 42.55 m).
TORONTO, ONTARIO (January 7, 2026) – TheNewswire – LAURION Mineral Exploration Inc. (TSX-V: LME | OTC: LMEFF | FSE: 5YD) (‘LAURION’ or the ‘Corporation’) is very pleased to report assay results of the first two drill holes from recent diamond drilling at the A-Zone/McLeod/CRK Zone at the Ishkōday Project, located in the Beardmore–Geraldton Greenstone Belt of north-western Ontario, approximately 220 kilometres northeast of Thunder Bay.
The current drill program focuses on the A-Zone/McLeod/CRK Zone, a structurally controlled gold-base metal corridor where historic drilling, surface work, and more recent LAURION drilling demonstrate repeated gold, silver, zinc, and copper mineralization along strike and at depth.
‘These results reinforce what we have been methodically building at Ishkōday — a structurally controlled gold-zinc system with repeated mineralization along a coherent corridor,‘ stated Cynthia Le Sueur Aquin, President and CEO of LAURION. ‘The combination of higher-grade intervals within broader mineralized zones, supported by both historic and recent drilling, gives us confidence that our targeting approach is working as intended. As we continue drilling, our focus remains on understanding continuity, structure, and scale.’
Drill hole LBX25-095 was designed to test a segment of the A-Zone/McLeod/CRK Zone structural corridor supported by proximal historic drill holes 90-41 and 90-49, as well as modern LAURION drill holes LBX20-021 and LBX20-017. Historic drill hole 90-41 intersected multiple gold-bearing intervals at various depths, including 0.55 m grading 3.69 g/t Au and 1.70% Zn, 0.55 m grading 11.88 g/t Au, 8.0 g/t Ag and 8.6% Zn, and deeper intersections including 0.91 m grading 1.63 g/t Au,16.0 g/t Ag, 0.16% Cu and 6.7% Zn, 0.66 m grading 2.12 g/t Au, 14.0 g/t Ag and 10.3% Zn, and 5.36 m grading 0.44 g/t Au, 6.16 g/t Ag and 4.28% Zn (Orient Resources Inc., Sturgeon River Property Diamond Drill Program Report, Claude Larouche, 1990). Nearby historic drill hole 90-49 returned 0.31 m grading 3.87 g/t Au and 1.73 m grading 3.46 g/t Au, 20.36 g/t Ag and 3.72% Zn (Orient Resources Inc., Claude Larouche, 1990). More recent drilling confirmed continuity of mineralization within the same corridor, including 14.08 m grading 0.89 g/t Au in drill hole LBX20-021 and additional gold-silver intervals in LBX20-017 (LAURION press release dated July 28, 2020).
Drill hole LBX25-095 intersected multiple gold-and-zinc-bearing intervals hosted within sheared and altered volcanic rocks consistent with the main A-Zone/McLeod/CRK Zone geological framework.
Reported assay results include 2.60 m grading 1.84 g/t Au from 27.40 to 30.00 m, including 0.60 m grading 7.25 g/t Au, 1.00 m grading 1.02 g/t Au from 45.30 to 46.30 m, and several broader intervals of lower-grade gold with elevated zinc.
A mid-depth mineralized zone returned 3.50 m grading 1.40 g/t Au and 2.30% Zn from 162.50 to 166.00 m, including a higher-grade interval of 0.70 m grading 5.97 g/t Au, 18.4 g/t Ag, 0.22% Cu and 10.8% Zn from 163.05 to 163.75 m.
Deeper in the hole, drilling intersected 4.50 m grading 2.00 g/t Au, 5.75 g/t Ag and 1.22% Zn from 188.00 to 192.50 m, including 0.50 m grading 3.30 g/t Au,17.8 g/t Ag and 6.84% Zn, 2.40 m grading 3.00 g/t Au, and 0.55 m grading 12.15 g/t Au,16.1 g/t Ag and 2.66% Zn.
Drill hole LBX25-096, located approximately 52 metres east of LBX25-095, was designed to test the eastern continuation of the same structurally controlled mineralized corridor. Targeting for LBX25-096 was informed by proximal drill holes LBX12-006, LBX20-020, and LBX22-089, which intersected gold-bearing mineralization within the same stratigraphic and structural package. Notably, drill hole LBX20-020 returned broad gold-bearing intervals including 6.86 m grading 0.47 g/t Au and 10.84 m grading 0.48 g/t Au, demonstrating mineralized width and continuity and supporting step-out drilling to the east (LAURION press release dated July 28, 2020). Drill hole LBX25-096 subsequently intersected multiple gold-bearing intervals within this corridor, including 3.85 m from 38.70 m to 42.55 m grading 1.92 g/t Au, including a higher-grade interval of 0.55 m from 42.00 m to 42.55 m grading 9.59 g/t Au, and a shallow interval of 1.15 m from 8.35 m to 9.50 m grading 2.14 g/t Au, including 0.50 m from 9.00 m to 9.50 m grading 4.76 g/t Au.
Gold mineralization at Ishkōday occurs within an orogenic gold framework and is commonly accompanied by silver, consistent with orogenic systems globally. In addition, localized enrichment in silver and base metals reflects polymetallic mineralizing events that are overprinted and locally modified by the orogenic gold event. These observations align with structural and geochemical interpretations supporting a multi-phase mineralizing history, as outlined in the Keaton Strongman Report 2024 on the Ishkōday: Ancestral structural controls between Archean epithermal and orogenic gold mineralization.
TABLE Of ASSAYS FOR DRILL HOLES LBX25-095 AND LBX25-096
|
Hole ID |
From (m) |
To (m) |
Core Length (m) |
Au (g/t) |
Ag (g/t) |
Zn (%) |
|
LBX25-095 |
27.40 |
30.00 |
2.60 |
1.84 |
0.45 |
0.02 |
|
including |
27.90 |
28.50 |
0.60 |
7.25 |
1.10 |
– |
|
LBX25-095 |
45.30 |
46.30 |
1.00 |
1.02 |
0.25 |
0.15 |
|
LBX25-095 |
91.25 |
95.25 |
4.00 |
0.11 |
0.25 |
0.01 |
|
LBX25-095 |
132.10 |
132.60 |
0.50 |
0.27 |
1.40 |
1.27 |
|
LBX25-095 |
135.20 |
135.70 |
0.50 |
0.53 |
6.10 |
0.24 |
|
LBX25-095 |
141.00 |
141.60 |
0.50 |
0.13 |
1.00 |
0.13 |
|
LBX25-095 |
143.80 |
147.80 |
4.00 |
0.12 |
1.71 |
0.17 |
|
LBX25-095 |
145.00 |
147.80 |
2.80 |
0.14 |
2.16 |
0.21 |
|
LBX25-095 |
162.50 |
166.00 |
3.50 |
1.40 |
4.27 |
2.30 |
|
Including |
163.05 |
163.75 |
0.70 |
5.97 |
18.40 |
10.80 |
|
LBX25-095 |
167.20 |
169.35 |
2.15 |
0.21 |
1.36 |
0.18 |
|
LBX25-095 |
188.00 |
192.50 |
4.50 |
2.00 |
5.75 |
1.22 |
|
Including |
188.00 |
188.50 |
0.50 |
3.30 |
17.80 |
6.84 |
|
Including |
190.10 |
192.50 |
2.40 |
3.00 |
4.80 |
0.78 |
|
Including |
191.1 |
192.50 |
0.55 |
12.15 |
16.10 |
2.66 |
|
LBX25-096 |
8.35 |
9.50 |
1.15 |
2.14 |
5.18 |
0.61 |
|
Including |
9.00 |
9.50 |
0.50 |
4.76 |
8.40 |
1.35 |
|
LBX25-096 |
10.90 |
11.40 |
0.50 |
0.52 |
0.70 |
0.02 |
|
LBX25-096 |
35.75 |
36.25 |
0.50 |
0.31 |
1.70 |
0.02 |
|
LBX25-096 |
38.70 |
42.55 |
3.85 |
1.92 |
2.41 |
0.13 |
|
Including |
40.60 |
41.20 |
0.60 |
2.78 |
6.30 |
0.62 |
|
Including |
42.00 |
42.55 |
0.55 |
9.59 |
5.50 |
0.11 |
|
LBX25-096 |
98.20 |
98.70 |
0.50 |
0.47 |
1.80 |
0.03 |
|
LBX25-096 |
106.80 |
108.50 |
1.70 |
1.19 |
1.49 |
0.07 |
|
Including |
106.80 |
107.30 |
0.50 |
3.14 |
2.20 |
0.07 |
|
LBX25-096 |
118.70 |
121.60 |
2.90 |
0.28 |
3.65 |
1.41 |
|
Including |
118.70 |
119.20 |
0.50 |
0.90 |
14.90 |
8.18 |
|
LBX25-096 |
129.60 |
130.10 |
0.50 |
2.22 |
10.10 |
3.05 |
|
Name |
Elevation |
Azimuth |
Dip |
Easting |
Northing |
Depth (m) |
|
LBX25-095 |
332.5 |
124 |
-47 |
446115.3 |
5512416 |
201 |
|
LBX25-096 |
331.4 |
125 |
-45 |
446168 |
5512429 |
168 |
|
TOTAL |
369 |
Mineralization on the A-Zone/McLeod/CRK Zone is interpreted to be controlled by the interaction of north–south-trending quartz-gold extensional veins and northeast–southwest-trending sulphide-rich shear veins. Reactivation of earlier sulphide zones during later deformation, locally associated with magnetite-rich assemblages, provides a structural framework that explains repeated gold enrichment, localized grade enhancement within wider base metal envelopes, and strong strike continuity beneath cover.
The current drilling on the A-Zone/McLeod/CRK Zone has focused on refining LAURION’s understanding of the geometry, continuity, and structural controls of the mineralized system. Ongoing work by the LAURION’s technical team and independent consultants is centred on consolidating historical and modern drilling, validating geological interpretations, and strengthening the 3D structural framework. This work is intended to ensure that any future technical milestones are based on a robust, well-constrained geological model, while preserving strategic flexibility as the Ishkōday Project continues to evolve.
Sampling and QA/QC Protocols
All drill core is transported and stored inside the core facility located at the Ishkōday Project in Greenstone, Ontario. LAURION employs an industry standard system of external standards, blanks and duplicates for all of its sampling, in addition to the QA/QC protocol employed by the laboratory. After logging, core samples were identified and then cut in half along core axis in the same building and then zip tied individually in plastic sample bags with a bar code. Approximately five or six of these individual bags were then stacked into a ‘rice’ white material bag and stored on a skid for final shipment to the laboratory.
All core samples were shipped to the ALS facility in Thunder Bay, Ontario, which were then prepared by ALS Global Geochemistry in Thunder Bay and analyzed by ALS Global Analytical Lab in North Vancouver, British Columbia. Samples are processed by 4-acid digestion and analyzed by fire assay on 50 g pulps and ICP-AES (Inductively Coupled Plasma – Atomic Emission Spectroscopy). Over limit analyses are reprocessed with gravimetric finish.
A total of 5% blanks and 5% standard are inserted randomly within all samples. 5% of the best assay result pulps were sent for re-assays. All QA/QC were verified, and no contamination or bias have been observed. The remaining half of the core, as well as the unsampled core, is stored in temporary core racks at the core logging facility in Beardmore and moved to the core storage facility at the Ishkōday Project.
Note: QA/QC review of standards and duplicates indicates analytical results are reliable. One zinc standard adjacent to a high-grade zinc interval returned elevated values consistent with expected analytical behaviour following high-grade samples.
Qualified Person
The technical contents of this release were reviewed and approved by Jean-Philippe Paiement, P.Geo, MSc, a consultant to LAURION and a Qualified Person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects.
About LAURION Mineral Exploration Inc.
The Corporation is a mid-stage junior mineral exploration and development company listed on the TSXV under the symbol LME and on the OTCPINK under the symbol LMEFF. LAURION now has 278,716,413 outstanding shares, of which approximately 73.6% are owned and controlled by insiders who are eligible investors under the ‘Friends and Family’ categories.
LAURION’s emphasis is on the exploration and development of its flagship project, the 100% owned mid-stage 57 km2 Ishkōday Project, and its gold-rich polymetallic mineralization.
LAURION’s chief priority remains maximizing shareholder value. A large portion of the Corporation’s focus in this regard falls within the scope of its mineral exploration activities and more specifically, advancing the Ishkōday Project. A consequence of LAURION’s success and advancement over the past several years is that the Corporation has become positioned as an acquisition target for appropriate potential acquirors. Accordingly, the Corporation’s Board of Directors is aware that possible strategic alternatives and transactional opportunities may arise and/or could be procured in the short or medium terms. The Corporation will promptly issue a press release if any material change occurs.
FOR FURTHER INFORMATION, CONTACT:
Laurion Mineral Exploration Inc.
Cynthia Le Sueur-Aquin – President and CEO
Tel: 1-705-788-9186 Fax: 1-705-805-9256
Douglas Vass – Investor Relations Consultant
Email: info@laurion.ca
Website: http://www.LAURION.ca
Follow us on: X (@LAURION_LME), Instagram (laurionmineral) and LinkedIn ()
Caution Regarding Forward-Looking Information
This press release contains forward-looking statements, which reflect the Corporation’s current expectations regarding future events including with respect to LAURION’s business, operations and condition, management’s objectives, strategies, beliefs and intentions, the Corporation’s ability to advance the Ishkōday Project, the nature, focus, timing and potential results of the Corporation’s exploration, drilling and prospecting activities in 2026 and beyond, including the Corporation’s diamond drill program described in this press release and the Corporation’s other planned activities for the Ishkōday Project for the remainder of 2026, and the statements regarding the Corporation’s exploration or consideration of any possible strategic alternatives and transactional opportunities, as well as the potential outcome(s) of this process, the possible impact of any potential transactions referenced herein on the Corporation or any of its stakeholders, and the ability of the Corporation to identify and complete any potential acquisitions, mergers, financings or other transactions referenced herein, and the timing of any such transactions. The forward-looking statements involve risks and uncertainties. Actual events and future results, performance or achievements expressed or implied by such forward-looking statements could differ materially from those projected herein including as a result of a change in the trading price of the common shares of LAURION, the TSX Venture Exchange or any other applicable regulator not providing its approval for any strategic alternatives or transactional opportunities, the interpretation and actual results of current exploration activities, changes in project parameters as plans continue to be refined, future prices of gold and/or other metals, possible variations in grade or recovery rates, failure of equipment or processes to operate as anticipated, the failure of contracted parties to perform, labor disputes and other risks of the mining industry, delays in obtaining governmental approvals or financing or in the completion of exploration, as well as those factors disclosed in the Corporation’s publicly filed documents. Investors should consult the Corporation’s ongoing quarterly and annual filings, as well as any other additional documentation comprising the Corporation’s public disclosure record, for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. Subject to applicable law, the Corporation disclaims any obligation to update these forward-looking statements. All sample values are from grab samples and channel samples, which by their nature, are not necessarily representative of overall grades of mineralized areas. Readers are cautioned to not place undue reliance on the assay values reported in this press release.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICE PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE.
Copyright (c) 2026 TheNewswire – All rights reserved.
News Provided by TheNewsWire via QuoteMedia
Here’s a quick recap of the crypto landscape for Monday (January 5) as of 9:00 p.m. UTC.
Get the latest insights on Bitcoin, Ether and altcoins, along with a round-up of key cryptocurrency market news.
Bitcoin (BTC) was priced at US$94,127.01, up by 3.2 percent over 24 hours.
Bitcoin price performance, January 6, 2025.
Chart via TradingView.
Bitcoin started Monday strong, rising above US$92,000 in early trading before briefly breaking US$94,600, signaling a potential shift in near-term momentum after a bruising finish to 2025.
Research firm 10X said the move reflects a return to more normalized trading volumes and early signs of renewed institutional positioning at the start of the year. The firm notes that Bitcoin is holding above key moving averages, with the 21 day line emerging as a critical support level for maintaining upside bias.
It added that the shift suggests growing expectations for a push toward the US$100,000 level. The rebound follows three consecutive monthly declines — a historically rare pattern that has often preceded January recoveries.
“The strength across crypto and traditional safe havens reflects a rebalancing phase driven by geopolitical risk and liquidity positioning,” said Lacie Zhang, a research analyst at Bitget Wallet.
“In this setup, Bitcoin has room to push toward US$105,000, while Ethereum could test US$3,600, as traders balance inflation risks with crypto’s deflationary characteristics and long-term adoption narrative.’
Zhang said DeFi is currently driving significant growth, with protocols such as Uniswap (UNI) and Aave (AAVE) seeing benefits from improved governance, new revenue-sharing frameworks and institutional investor involvement.
“For large-cap altcoins, XRP and Solana stand out: XRP’s role in cross-border payments and improving regulatory clarity, combined with ETF inflows, could support price ranges of US$5 – US$10, while Solana’s high-throughput ecosystem and network expansion position it for US$500 – US$800 over the next growth phase.
“The renewed surge in memecoin activity reflects improving retail risk appetite,” she added. “It’s not a long-term thesis, but often a precursor to liquidity rotating into higher-quality, utility-driven altcoins as the cycle matures.”
Ether (ETH) was priced at US$3,239.82, up by 3.2 percent over the last 24 hours.
Global crypto exchange-traded products attracted US$47.2 billion in net inflows in 2025, falling just short of the prior year’s record despite a noticeable slowdown in Bitcoin demand, according to CoinShares.
Bitcoin-focused products added US$26.9 billion, a sharp drop from 2024 levels, as price weakness dampened inflows and modest interest emerged in short-bitcoin vehicles. The cooling in Bitcoin was offset by a surge into select altcoins, led by Ethereum products, which posted US$12.7 billion in inflows.
Meanwhile, XRP and Solana funds followed closely as each recorded multibillion-dollar inflows and triple-digit percentage growth year over year.
Satsuki Katayama, Japan’s finance minister, has signaled stronger government backing for integrating digital assets into the country’s stock and commodities exchanges.
Speaking at the Tokyo Stock Exchange, she emphasized the role of exchanges in expanding public access to blockchain-based assets and modern investment tools. She pointed to the US experience with crypto-linked exchange-traded funds (ETFs) as a reference point, even as Japan currently lacks domestically listed crypto ETFs.
Katayama described 2026 as a “digital year,” pledging policy support for exchanges adopting advanced trading technologies. The remarks build on regulatory reforms already underway, including discussions on allowing banks to hold crypto assets and the approval of Japan’s first yen-pegged stablecoin.
Bitget’s new Universal Exchange vision has reached two major milestones that signal a major shift in how digital and traditional assets are traded in one place. Bitget announced last week that its tokenized stock volume surpassed US$1 billion, with 95 percent of that total volume occurring in December alone.
Building on that momentum, and following a successful private beta with over 80,000 users, today Bitget officially opened its TradFi trading suite to the public, allowing customers access to 79 different instruments across forex, metals, indices and commodities. These products are traded as contracts for difference and are settled entirely in USDT, meaning crypto-native traders can execute macro strategies without leaving the platform or converting to fiat currency.
During the test phase, XAU/USD recorded over US$100 million in single-day trading volume, one of the highest daily figures observed during the beta.
“Traders want the flexibility to choose between assets in a unified ecosystem,” said Chen.
“They want the freedom to move between crypto and traditional markets as conditions change. TradFi going public is about giving them that accessibility in one place, without friction.”
The move signals a broader shift in how exchanges are evolving, not just as venues for speculation, but as comprehensive gateways to global markets under a unified trading experience.
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.
Altech Batteries (ATC:AU) has announced Altech – CERENERGY Project Secures German Grant Approval
Download the PDF here.
From established players to up-and-coming firms, Canada’s pharmaceutical landscape is diverse and dynamic.
Canadian drug companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are playing a role in the landscape as well.
Read on to learn about what’s been driving the share prices of the best-performing Canadian pharma stocks.
Year-on-year gain: 26.6 percent
Market cap: C$149.8 million
Share price: C$4.76
HLS Therapeutics focuses on drugs for cardiovascular and central nervous system problems, often through partnerships. The company specializes in acquiring and commercializing pharmaceuticals that address unmet needs, including Vascepa to reduce cardiovascular risk and Clozaril for treatment-resistant schizophrenia.
HLS in-licensed the exclusive rights to the treatments Nilemdo and Nexlizet, both of which are already approved in other countries, from Esperion (NASDAQ:ESPR) in May.
The November 2025 Health Canada approval of LDL-cholesterol lowering treatment Nilemdo represents the most significant catalyst for the company since the launch of Vascepa, positioning HLS as a dominant leader in the Canadian cardiovascular market. The company is targeting Nilemdo’s commercial launch in Q2 2026.
Along with the approval, Health Canada issued a notice of non-compliance for its Nexlizet cholesterol-reducing treatment. According to HLS, the decision was related to chemistry, manufacture and controls data, not clinical data or safety.
Additionally, the company generates revenue from a diversified portfolio of royalty interests on various products marketed by third parties.
Year-on-year gain: 14.49 percent
Market cap: C$141.04 million
Share price: C$0.79
Satellos Bioscience is a Canadian pharmaceutical company expanding treatment options for muscle disorders. The company has focused specifically on Duchenne muscular dystrophy, developing therapies that target the specific biological pathways involved in regenerating and repairing muscle tissue.
Its lead candidate, SAT-3247, targets a protein called AAK1, which regulates the activity of stem cells that activate and differentiate new muscle fibers.
In Q4 2025, Satellos administered the first dose to a patient in its 11-month open-label follow-up study for adults who completed its initial Phase 1b trial. The study seeks to demonstrate the lasting impact of the significant functional improvements observed earlier in the year.
On December 9, the company received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) and several other global regulators to initiate BASECAMP, a global Phase 2 randomized, placebo-controlled study to evaluate SAT-3247 in pediatric patients.
Year-on-year gain: 14.29 percent
Market cap: C$592.59 million
Share price: C$6.00
Knight Therapeutics is a specialty pharmaceutical company headquartered in Montreal, Québec. It operates on an acquisition and in-licensing model, obtaining the rights to innovative medicines from global pharmaceutical companies and commercializing them across Canada and Latin America.
The company was originally founded by the former leaders of Paladin Labs, which was acquired by Endo International in 2014. In June 2025, Knight bought the Paladin business back from Endo for C$107 million, adding over 40 products to Knight’s Canadian roster.
The additions, helped drive 32 percent revenue growth year-over-year to a record C$122.55 million in Q3. The company projects its Knight Canada subsidiary will be the company’s top revenue-contributor within two years.
Year-on-year gain: 10.07 percent
Market cap: C$146.89 million
Share price: C$12.90
BioSyent is a specialty pharmaceutical company focused on in-licensing or acquiring established, high-margin healthcare products for the Canadian and international markets. Its growth is anchored by brands in iron health and women’s wellness. Its flagship brand, FeraMAX, has been Canada’s leading iron supplement for over a decade.
The company’s 2024 acquisition of Tibella, a treatment for menopausal symptoms, has been a major growth driver. According to its Q3 earnings report. BioSyent’s sales grew 19 percent year-over-year in Canada and 94 percent in the international market.
Year-on-year gain: 6.45 percent
Market cap: C$47.54 million
Share price: C$0.66
NurExone Biologic is behind ExoTherapy, a drug-delivery platform that uses exosomes, which are nano-sized extracellular vesicles, to create treatments for central nervous system disorders, spinal cord injuries and traumatic brain injuries. It is a less invasive alternative to cell transplantation, which requires surgery and carries the risk of rejection.
NurExone’s first nano-drug, ExoPTEN, uses a proprietary sIRNA sequence delivered with the ExoTherapy platform to treat spinal cord injuries. ExoPTEN received orphan drug designation from the US FDA in October 2023.
The company expects to initiate its Phase 1/2a first-in-human trial for acute spinal cord injury in the second half of 2026, targeting patients with traumatic injuries.
It continues to make significant progress, with recent preclinical studies demonstrating strong, dose-dependent vision recovery in glaucoma models and improved motor function in spinal cord injury models.
The company announced plans for a US exosome production facility in Indianapolis, Indiana, in September. According to the release, ‘The GMP compliant site would produce exosomes both for NurExone’s therapeutic pipeline and for a growing business-to-business opportunity in regenerative aesthetics.’
In December, the company began planning for small-scale production of ExoPTEN in Israel to support its clinical trial.
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
Highlights
– Altech Batteries GmbH’s CERENERGY(R) battery project has received conditional binding funding approval under Germany’s federal ‘STARK’ economic development program.
– The approval relates to a grant covering approximately 30% of eligible project CAPEX, with funding of up to EUR46.11M.
– The funding commitment is conditional on achieving full project financial close by 30 June 2026 and parliamentary approval of funds under Germany’s 2026 Federal Budget.
Conditional Binding Funding Commitment
The funding is being provided as part of the federal STARK program, which is supported by the Federal Ministry for Economic Affairs and Energy in cooperation with the EU. The aim of this program is to lead regions undergoing structural change into an ecologically, economically and socially sustainable future.
With the approval of the funding, the project has successfully completed the second and decisive stage of the approval process. The funding covers approximately 30% of the eligible investment costs and represents a significant milestone for the construction of the planned 120 MWh CERENERGY(R) battery factory in Germany.
This decision underscores the importance of the innovative CERENERGY(R) technology, which is being developed in collaboration with the Fraunhofer Society. The Sodium-Chloride Solid-State battery offers a safe, sustainable and strategically independent alternative to lithium-ion batteries and is expected to play an important role in future stationary energy storage solutions – especially for the European market.
Mr Daniel Raihani, Managing Director & Chief Executive Officer, commented ‘Securing conditional binding funding approval of up to EUR46.11 million under Germany’s STARK program is a major milestone for the CERENERGY(R) project. The support reflects the strategic importance of establishing advanced, nonlithium energy storage manufacturing capability in Europe and recognises the technical progress achieved to date in collaboration with Fraunhofer IKTS.
‘Importantly, the grant materially de-risks the project’s capital structure by covering approximately 30% of eligible investment costs and provides a strong foundation as we progress toward full project financing and construction of the planned 120 MWh production facility in Saxony, Germany.
‘We remain focused on completing financial close by mid-2026 and advancing the CERENERGY(R) technology toward commercial deployment to support long-duration, safe and sustainable stationary energy storage solutions for the European market’.
As is customary for projects of this size, the funding commitment is subject to final financial close of the CERENERGY(R) battery project by June 2026 and budgetary approval of the funds in the 2026 federal budget.
*To view tables and figures, please visit:
https://abnnewswire.net/lnk/918BT5H8
About Altech Batteries Ltd:
Altech Batteries Limited (ASX:ATC,OTC:ALTHF) (FRA:A3Y) is a specialty battery technology company that has a joint venture agreement with world leading German battery institute Fraunhofer IKTS (‘Fraunhofer’) to commercialise the revolutionary CERENERGY(R) Sodium Alumina Solid State (SAS) Battery. CERENERGY(R) batteries are the game-changing alternative to lithium-ion batteries. CERENERGY(R) batteries are fire and explosion-proof; have a life span of more than 15 years and operate in extreme cold and desert climates. The battery technology uses table salt and is lithium-free; cobalt-free; graphite-free; and copper-free, eliminating exposure to critical metal price rises and supply chain concerns.
The joint venture is commercialising its CERENERGY(R) battery, with plans to construct a 100MWh production facility on Altech’s land in Saxony, Germany. The facility intends to produce CERENERGY(R) battery modules to provide grid storage solutions to the market.
Source:
Altech Batteries Ltd
Contact:
Daniel Raihani
Managing Director
Altech Batteries Limited
Tel: +61-8-6168-1555
Email: info@altechgroup.com
Martin Stein
Chief Financial Officer
Altech Batteries Limited
Tel: +61-8-6168-1555
Email: info@altechgroup.com
News Provided by ABN Newswire via QuoteMedia
Centurion Minerals offers investors an early-stage entry point into a strategically located gold exploration company positioned within one of North America’s most prolific and active mining districts. With a restructured corporate foundation, and a highly experienced geological and corporate finance team, the company is primed for value-creating discoveries.
Centurion Minerals (TSXV:CTN) is a Canadian exploration company focused on the acquisition, exploration and development of precious metals projects in the Americas.
The company’s strategy is centered on advancing high-quality, early-stage gold assets through systematic exploration to define drill-ready targets and unlock the discovery potential inherent in its three-part claim package: the Newman, Noseworthy and Hepburn properties. Situated near major operations and new discoveries, these claims benefit from excellent infrastructure, year-round road access and proximity to proven mineralized structural corridors. Centurion intends to increase shareholder value through targeted geophysics, ground truthing and drilling programs designed to reveal new high-grade zones, as well as through potential future acquisitions of complementary gold assets across the Americas.
Backed by a leadership team with decades of exploration, geology, corporate finance and project development experience, Centurion is positioned to capitalize on strong gold market fundamentals and renewed investor interest in junior exploration companies. With a low current valuation and advancing work program, the company provides leverage to both exploration success and broader trends in the gold sector.
The Casa Berardi West project is Centurion’s flagship gold exploration asset, encompassing approximately 6,732 hectares across three contiguous claim groups – Newman, Noseworthy and Hepburn – located 66 km northeast of Cochrane, Ontario. The project sits along structural corridors that host some of the region’s most significant deposits, including Hecla Mining’s Casa Berardi mine (3 Moz past production, plus 4 Moz in reserves and resources), Agnico Eagle’s Detour Lake mine (15 Moz reserve, producing ~659,000 oz of gold per year ), and AMEX Exploration’s Perron discovery (1.6 Moz measured and indicated resource at 6.14 g/t gold).
Location of the three claim groups at Casa Berardi West
The project is situated within the central north Abitibi Subprovince, an Archean greenstone belt known globally for its prolific endowment of gold and base metals. The claims lie adjacent to geological features associated with multiple major deposits – iron formations, shear zones and VMS trends – creating strong analogues to high-grade gold mines such as the Musselwhite mine in Northern Ontario.
This “closeology” positioning significantly enhances the potential for Centurion’s ground to host similar mineralization.
Historic exploration across the Casa Berardi West project – spanning more than 70 RC and diamond drill holes – has already confirmed the presence of gold-bearing structures and favorable host rocks. Notably, previous work returned multiple samples above 1 g/t gold, including a standout result of 38 g/t gold, demonstrating strong mineralization potential across the claim area.
Significant historic drill results at Newman target
Across the three claim groups, drilling and geophysical surveys have identified key geological features associated with major deposits in the region, including iron formations, shear zones and sulphidized horizons. Several zones of interest remain untested or underexplored, particularly along structural trends that extend from nearby high-grade gold and VMS systems such as the Perron and Normetal areas.
These findings provide Centurion with multiple high-priority target areas for follow-up exploration, forming the foundation for its next phase of geophysical work and upcoming drill targeting.
David Tafel brings over 30 years of experience in corporate structuring, strategic planning, financing and executive management across multiple public and private resource companies. He has raised several hundred million dollars for ventures in mining, technology and life sciences, and previously managed private investment funds at Canada’s largest independent securities firm.
A seasoned financial executive with more than 20 years of experience, Jeremy Wright serves as president & CEO of Seatrend Strategy Group and has held CFO roles across numerous public companies in the resource and technology sectors. His background includes financial management, negotiations and environmental economics, supported by extensive board leadership experience.
Joseph Del Campo has served as CFO and Interim CEO across several mining companies, including Unigold and First Nickel. With decades of corporate financial leadership and board experience, he contributes deep governance, audit and operational oversight expertise to Centurion’s board.
A veteran geologist with 40+ years of industry experience, Mike Kilbourne has managed over 100,000 metres of drilling across North America and Mexico, worked as a production geologist in multiple mining environments, and generated over 700 exploration targets for private and public companies.
Jamie Lavigne is a senior exploration geologist with more than 30 years of experience in base and precious metals. He has held senior technical roles with major mining companies and specializes in advanced exploration, resource delineation and geological modeling across global mineral belts.